Trodelvy Now Approved for Pretreated Patients with HR-Positive, HER2-Negative Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 14
- Publication type:
- Article
Works matching IS 21534888 AND DT 2023 AND VI 14 AND IP 2
Results: 16
1
2
Jemperli Receives Regular FDA Approval for Advanced Endometrial Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 14
- Publication type:
- Article
3
FDA Expands Indication for Verzenio as Adjuvant Treatment for HR-Positive, HER2-Negative, Early Breast Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 14
- Publication type:
- Article
4
Tafinlar plus Mekinist Combination Approved for Pediatric Low-Grade Glioma with BRAF<sup>V600E</sup> Mutation.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 13
- Publication type:
- Article
5
Zynyz Receives FDA Accelerated Approval for Merkel-Cell Carcinoma.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 13
- Publication type:
- Article
6
Survey Shows Inflation Affecting Majority of Consumer Healthcare Decisions.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 13
- By:
- Publication type:
- Article
7
Researchers Predict Rise in Cholangiocarcinoma Incidence Over the Next 10 Years.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 12
- Publication type:
- Article
8
Cost-Effectiveness of GemCis with or without Durvalumab in Patients with Advanced Cholangiocarcinoma.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 12
- Publication type:
- Article
9
Cybersecurity Framework Implementation Guide Helps Healthcare Organizations Manage Risk.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 10
- By:
- Publication type:
- Article
10
New Subgroup Analysis Confirms Efficacy and Safety of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate Cancer.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 7
- By:
- Publication type:
- Article
11
Choosing Adjuvant Treatment for Patients with RCC Requires Careful Consideration of Risks and Benefits.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 6
- By:
- Publication type:
- Article
12
What Will It Take to End Cancer As We Know It?
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 6
- By:
- Publication type:
- Article
13
ACS Reports Shift in Colorectal Cancer to Advanced Stage and Younger Age at Diagnosis.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 1
- By:
- Publication type:
- Article
14
FDA Updates Mammography Regulations to Require Reporting of Breast Density Information.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 1
- By:
- Publication type:
- Article
15
Study Reveals Alarming Disparities in Opioid Access Among Patients with Cancer at End of Life.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 2, p. 1
- Publication type:
- Article
16
Addressing Health Equity in Bladder Cancer Care.
- Published in:
- 2023
- By:
- Publication type:
- Proceeding